NAD+, NR, and NMN: Different Substances, Different Evidence
NAD+ is a coenzyme involved in cellular metabolism. NR and NMN are related precursors, not alternative names for the same product.
By PacificRx editorial team · Published
At a glance
NAD+ is a coenzyme involved in cellular metabolism. NR and NMN are related precursors, not alternative names for the same product. Evidence for a particular substance, route, and outcome should not be generalized to every supplement, injection, or infusion described as supporting NAD.
- NAD+ is a coenzyme, not a peptide.
- Precursor and infusion studies answer different questions.
- A biomarker change does not prove a longevity benefit.
On this page
Why do the names appear together?
NAD metabolism involves several related molecules, so discussions of cellular energy often mention NAD+, nicotinamide riboside, and nicotinamide mononucleotide together. A shared pathway does not make these substances chemically identical or establish that their products have the same effects.
A product's route also matters. An oral precursor, an oral preparation labeled NAD+, and an intravenous preparation pose different questions about delivery, metabolism, tolerability, and preparation quality.
How should I compare research?
Start with the exact substance and route in the original study. Identify the participants, comparison group, dose protocol, duration, and outcomes. Do not treat a change in a measured metabolite as proof of improved symptoms, physical function, or lifespan.
The original human NAD+ infusion pilot examined metabolic observations under a specific infusion protocol. Such exploratory work does not establish that every commercial NAD-related product provides a meaningful clinical benefit.
What should I ask before considering a product?
Ask which human evidence supports the actual formulation and goal, what remains uncertain, and what follow-up would measure. For injectable or intravenous preparations, discuss sterile-compounding quality and the dispensing pharmacy separately from the biological rationale.
The FDA has warned about unsuitable ingredients used in sterile compounding, including food-grade NAD+ in intravenous products. A general claim about cellular metabolism does not answer those product-quality questions.